BR112015023332A2 - Toxóide, composições e método relacionados - Google Patents
Toxóide, composições e método relacionadosInfo
- Publication number
- BR112015023332A2 BR112015023332A2 BR112015023332A BR112015023332A BR112015023332A2 BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2 BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A BR112015023332 A BR 112015023332A BR 112015023332 A2 BR112015023332 A2 BR 112015023332A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- toxoid
- compositions
- inactivating
- toxoids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- 231100000765 toxin Toxicity 0.000 abstract 3
- 239000003053 toxin Substances 0.000 abstract 3
- 108700012359 toxins Proteins 0.000 abstract 3
- 241000193163 Clostridioides difficile Species 0.000 abstract 2
- 230000000415 inactivating effect Effects 0.000 abstract 2
- 231100001102 clostridial toxin Toxicity 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 231100000065 noncytotoxic Toxicity 0.000 abstract 1
- 230000002020 noncytotoxic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790423P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029035 WO2014144567A2 (en) | 2013-03-15 | 2014-03-14 | Toxoid, compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015023332A2 true BR112015023332A2 (pt) | 2017-08-22 |
Family
ID=50489430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015023332A BR112015023332A2 (pt) | 2013-03-15 | 2014-03-14 | Toxóide, composições e método relacionados |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160045586A1 (https=) |
| EP (1) | EP2968507A2 (https=) |
| JP (1) | JP2016516721A (https=) |
| KR (1) | KR20150133770A (https=) |
| CN (1) | CN105338997A (https=) |
| AR (1) | AR095669A1 (https=) |
| AU (1) | AU2014228956A1 (https=) |
| BR (1) | BR112015023332A2 (https=) |
| CA (1) | CA2907154A1 (https=) |
| HK (1) | HK1213800A1 (https=) |
| SG (1) | SG11201507608PA (https=) |
| TW (1) | TWI624474B (https=) |
| WO (1) | WO2014144567A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| JP6691477B2 (ja) * | 2013-06-14 | 2020-04-28 | サノフィ パストゥール インコーポレイテッド | クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法 |
| BR112017024443A2 (pt) * | 2015-05-15 | 2018-10-23 | Sanofi Pasteur Inc | métodos para imunização contra clostridium difficile |
| US11154605B2 (en) | 2017-06-09 | 2021-10-26 | Hipra Scientific, S.L.U. | Vaccine comprising Clostridium toxoids |
| US10096313B1 (en) * | 2017-09-20 | 2018-10-09 | Bose Corporation | Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices |
| EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| JP2024546686A (ja) * | 2021-12-06 | 2024-12-26 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | 癌を治療するための組成物及び方法 |
| CN120615016A (zh) | 2023-02-02 | 2025-09-09 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| US5610023A (en) * | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
| EP2305293A3 (en) * | 1997-10-20 | 2013-11-06 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6669520B2 (en) | 2001-09-19 | 2003-12-30 | United Microelectronics Corp. | Method of fabricating an LC panel |
| MX2010001054A (es) | 2007-07-26 | 2010-04-21 | Sanofi Pasteur Ltd | Composiciones adyuvantes antigenicas y metodos. |
| HUE037932T2 (hu) | 2007-09-14 | 2018-09-28 | Sanofi Pasteur Biologics Llc | Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók |
| GB201011968D0 (en) * | 2010-07-16 | 2010-09-01 | Secr Defence | Toxoiding method |
-
2014
- 2014-03-14 KR KR1020157029566A patent/KR20150133770A/ko not_active Withdrawn
- 2014-03-14 US US14/776,145 patent/US20160045586A1/en not_active Abandoned
- 2014-03-14 EP EP14717950.1A patent/EP2968507A2/en not_active Withdrawn
- 2014-03-14 CN CN201480021368.4A patent/CN105338997A/zh active Pending
- 2014-03-14 BR BR112015023332A patent/BR112015023332A2/pt not_active IP Right Cessation
- 2014-03-14 HK HK16101854.5A patent/HK1213800A1/zh unknown
- 2014-03-14 SG SG11201507608PA patent/SG11201507608PA/en unknown
- 2014-03-14 JP JP2016502966A patent/JP2016516721A/ja active Pending
- 2014-03-14 AU AU2014228956A patent/AU2014228956A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029035 patent/WO2014144567A2/en not_active Ceased
- 2014-03-14 CA CA2907154A patent/CA2907154A1/en not_active Abandoned
- 2014-03-17 TW TW103110044A patent/TWI624474B/zh not_active IP Right Cessation
- 2014-03-18 AR ARP140101275A patent/AR095669A1/es unknown
-
2017
- 2017-10-02 US US15/722,029 patent/US20180028637A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180028637A1 (en) | 2018-02-01 |
| SG11201507608PA (en) | 2015-10-29 |
| JP2016516721A (ja) | 2016-06-09 |
| KR20150133770A (ko) | 2015-11-30 |
| US20160045586A1 (en) | 2016-02-18 |
| CA2907154A1 (en) | 2014-09-18 |
| WO2014144567A2 (en) | 2014-09-18 |
| AR095669A1 (es) | 2015-11-04 |
| WO2014144567A3 (en) | 2014-12-04 |
| TW201514197A (zh) | 2015-04-16 |
| AU2014228956A1 (en) | 2015-10-08 |
| CN105338997A (zh) | 2016-02-17 |
| HK1213800A1 (zh) | 2016-07-15 |
| TWI624474B (zh) | 2018-05-21 |
| EP2968507A2 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023332A2 (pt) | Toxóide, composições e método relacionados | |
| CR20200082A (es) | Virus chikungunya inmunogénico | |
| SG10201808151RA (en) | Cortistatin analogues and syntheses and uses thereof | |
| BR112016012870A2 (pt) | ?métodos e composições para melhorar a produção de alface | |
| PH12013502442A1 (en) | Inactivated dengue virus vaccine | |
| MX2017004617A (es) | Variantes estabilizadas de alfa amilasa y su uso. | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| PH12018502120A1 (en) | Live attenuated alphavirus constructs and methods and uses thereof | |
| MX2015011228A (es) | Sales de glicopirrolato. | |
| PH12015501888A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| PH12014502763A1 (en) | Method for the degradation of keratin and use of the keratin hydrolysate produced | |
| BR112015031913A2 (pt) | processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização | |
| BR112017000022A2 (pt) | nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas | |
| NZ738538A (en) | 6-amino-quinoline-3-carbonitrils as cot modulators | |
| AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
| BR112013025424A2 (pt) | processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica | |
| UA116697C2 (uk) | Композиція для запобігання зараженню видами роду mycoplasma | |
| BR102014009838B8 (pt) | Método para produzir um l-aminoácido | |
| BR112014029264A2 (pt) | microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo | |
| BR112015027824A2 (pt) | composições de vitamina e em pó | |
| BR112017023969A2 (pt) | ?microrganismo do gênero escherichia que produz l-triptofano e um método para produzir l- triptofano com o uso do mesmo? | |
| PH12015502115B1 (en) | Compositions and methods for live, attenuated alphavirus formulations | |
| MY174818A (en) | Immunogenic compostion comprising mycoplasma antigens | |
| BR112018075794A2 (pt) | produção de neurotoxinas clostridiais ativadas | |
| BR112017024443A2 (pt) | métodos para imunização contra clostridium difficile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 07/01/2020. |